Insider Transactions in Q2 2021 at Evofem Biosciences, Inc. (EVFM)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2021
|
Kim P. Kamdar Director |
BUY
Open market or private purchase
|
Direct |
10,000
+34.14%
|
$10,000
$1.17 P/Share
|
|
Jun 14
2021
|
Anthony Stephen O'Brien Director |
BUY
Open market or private purchase
|
Direct |
8,140
+50.0%
|
$8,140
$1.31 P/Share
|
|
Jun 11
2021
|
Lisa Dale Rarick Director |
BUY
Open market or private purchase
|
Direct |
5,000
+32.79%
|
$5,000
$1.2 P/Share
|
|
Jun 11
2021
|
Russell Barrans Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
18,180
+3.74%
|
$18,180
$1.14 P/Share
|
|
Jun 10
2021
|
Alexander A Fitzpatrick General Counsel and Secretary |
BUY
Open market or private purchase
|
Direct |
10,000
+3.11%
|
$10,000
$1.02 P/Share
|
|
Jun 10
2021
|
Saundra L Pelletier Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+5.55%
|
$50,000
$1.03 P/Share
|
|
Jun 10
2021
|
Justin J. File Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
24,500
+5.27%
|
$24,500
$1.03 P/Share
|
|
May 20
2021
|
Saundra L Pelletier Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
105,300
-11.62%
|
$0
$0.86 P/Share
|
|
May 20
2021
|
Justin J. File Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
42,280
-9.23%
|
$0
$0.86 P/Share
|
|
May 20
2021
|
Kelly Culwell Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
42,061
-13.33%
|
$0
$0.86 P/Share
|
|
May 20
2021
|
Russell Barrans Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
31,480
-6.53%
|
$0
$0.86 P/Share
|
|
May 20
2021
|
Alexander A Fitzpatrick General Counsel and Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
42,120
-12.26%
|
$0
$0.86 P/Share
|